Johnson & Johnson Bolsters Its Oncology Pipeline With Nanobiotix Radiotherapy Pact

Nanobiotix NBTX shares are trading higher after the company announced a global licensing, co-development, and commercialization agreement with Janssen Pharmaceutica NV, a unit of Johnson & Johnson JNJ, for the investigational radioenhancer NBTXR3.

Johnson & Johnson has bolstered its oncology pipeline with the licensing agreement for the drug designed to enhance the effectiveness of radiotherapy for solid tumors.

Janssen will pay $60 million in upfront fees and funding for an exclusive worldwide license.

NBTXR3 has been approved in Europe as Hensify as a treatment for locally-advanced soft tissue sarcomas.

NBTXR3 is currently being evaluated in several studies across solid tumor indications, including NANORAY-312 Phase 3 study for locally advanced head and neck cancer. 

NBTXR3 is also being evaluated for its potential as a systemic agent in combination with anti-PD-1 immune checkpoint inhibitors for patients with metastatic cancers.

Janssen will pay up to $30 million to complete NANORAY-132 as part of its upfront support. It has also pledged up to $1.8 billion in development, regulatory, and sales milestones in head and neck cancer.

The agreement also includes additional potential milestone payments of up to $650 million for five new indications that Janssen may develop at its sole discretion; and of up to $220 million per indication that Nanobiotix may develop in alignment with Janssen.

Price Action: NBTX shares are up 36.10% at $7.10 on the last check Monday.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!